Basic Information
| LncRNA/CircRNA Name | SNHG5 |
| Synonyms | SNHG5, C6orf160, LINC00044, NCRNA00044, U50HG, bA33E24.2 |
| Region | GRCh38_6:85660950-85678736 |
| Ensemble | ENSG00000203875 |
| Refseq | NR_003038 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, Western blot, in vitro knockdown |
| Sample | BC tissues, Bladder cancer cell lines (SW780, UMUC3, 5637, T-24) |
| Expression Pattern | up-regulated |
| Function Description | SNGH5 was found upregulated in BC tissues and cell lines and a high level of SNGH5 was correlated with a poor prognosis. Silencing SNHG5 inhibited the proliferation ability of BC cells and such a function was attributed to its influence on cells cycle and apoptosis. |
| Pubmed ID | 29434891 |
| Year | 2017 |
| Title | lncRNA SNHG5 is associated with poor prognosis of bladder cancer and promotes bladder cancer cell proliferation through targeting p27. |
External Links
| Links for SNHG5 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |